The potential of activator protein 1 (AP-1) in cancer targeted therapy

被引:31
|
作者
Song, Dandan [1 ]
Lian, Yan [2 ]
Zhang, Lin [1 ]
机构
[1] Qingdao Univ, Clin Med Res Ctr Women & Children Dis, Key Lab Birth Defect Prevent & Genet Med, Shandong Hlth Commiss,Shandong Prov Maternal & Chi, Jinan, Peoples R China
[2] Qingdao Univ, Dept Obstet, Shandong Prov Maternal & Child Hlth Care Hosp, Jinan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
AP-1; Jun; Fos; cancer; targeted therapy; FOS FAMILY-MEMBERS; T-CELL EXHAUSTION; C-JUN; BREAST-CANCER; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; INHIBITOR; FRA-1; POLY(ADP-RIBOSE);
D O I
10.3389/fimmu.2023.1224892
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activator protein-1 (AP-1) is a transcription factor that consists of a diverse group of members including Jun, Fos, Maf, and ATF. AP-1 involves a number of processes such as proliferation, migration, and invasion in cells. Dysfunctional AP-1 activity is associated with cancer initiation, development, invasion, migration and drug resistance. Therefore, AP-1 is a potential target for cancer targeted therapy. Currently, some small molecule inhibitors targeting AP-1 have been developed and tested, showing some anticancer effects. However, AP-1 is complex and diverse in its structure and function, and different dimers may play different roles in different type of cancers. Therefore, more research is needed to reveal the specific mechanisms of AP-1 in cancer, and how to select appropriate inhibitors and treatment strategies. Ultimately, this review summarizes the potential of combination therapy for cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] EXPRESSION OF ACTIVATOR PROTEIN-1 (AP-1) FAMILY MEMBERS IN THE HUMAN EPIDERMIS AND IN CULTURED KERATINOCYTES
    WELTER, JF
    ECKERT, RL
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (04) : 674 - 674
  • [22] Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion
    Young, MR
    Li, JJ
    Rincón, M
    Flavell, RA
    Sathyanarayana, BK
    Hunziker, R
    Colburn, N
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) : 9827 - 9832
  • [23] FOS PROTEIN COMPLEX BINDS TO THE RECOGNITION SEQUENCE OF THE HELA-CELL ACTIVATOR PROTEIN-1 (AP-1)
    CURRAN, T
    RAUSCHER, FJ
    SAMBUCETTI, LC
    FRANZA, BR
    CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, 1988, : 175 - 189
  • [24] Laa1p, a conserved AP-1 accessory protein important for AP-1 localization in yeast
    Fernandez, G. Esteban
    Payne, Gregory S.
    MOLECULAR BIOLOGY OF THE CELL, 2006, 17 (07) : 3304 - 3317
  • [25] AP-1 a target for cancer prevention
    Matthews, Connie P.
    Colburn, Nancy H.
    Young, Matthew R.
    CURRENT CANCER DRUG TARGETS, 2007, 7 (04) : 317 - 324
  • [26] AP-1 (Fos/Jun) and cancer
    Wagner, E. F.
    FEBS JOURNAL, 2006, 273 : 21 - 22
  • [27] Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells
    Gopalakrishnan, Avanthika
    Xu, Chang-Jiang
    Nair, Sujit S.
    Chen, Chi
    Hebbar, Vidya
    Kong, Ah-Ng Tony
    ARCHIVES OF PHARMACAL RESEARCH, 2006, 29 (08) : 633 - 644
  • [28] Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells
    Avanthika Gopalakrishnan
    Chang -Jiang Xu
    Sujit S Nair
    Chi Chen
    Vidya Hebbar
    Ah -Ng Tony Kong
    Archives of Pharmacal Research, 2006, 29
  • [29] Does, AP-1 upregulation in androgen refractory prostate cancer identify a subset of patients suitable for AP-1 specific targetted therapy?
    Nalagatla, SK
    Edwards, J
    Underwood, MA
    Grigor, K
    Bartlett, J
    JOURNAL OF UROLOGY, 2003, 169 (04): : 88 - 88
  • [30] Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
    Meijer, C. Arnoud
    Le Haeni, Pum A. A.
    van Dijk, Rogier A.
    Hira, Mitsuhisa
    Hamming, Jaap F.
    van Bockel, J. Hajo
    Lindeman, Jan H.
    CLINICAL SCIENCE, 2012, 122 (9-10) : 421 - 428